Posts

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

on

Wave aims for monthly dosing with RNA editing treatment for AATD now targets a monthly injection schedule for its WVE‑006 program in AATD.

on

Apogee Therapeutics' Phase 2 Data Positions Zumilokibart (APG777) as Convenient Alternative to Dupixent and Ebglyss in Eczema Treatment

on

Shaping What's Next in Drug Delivery: 2026 Trends and Innovations

on

Ascletis Reports Positive Phase 2 Data for Quarterly-Dosing GLP-1 ASC30 in Obesity

on

Biopharma Bites: uniQure Pauses AMT-191 Dosing, GSK's Nucala Gets EU Nod, Gilead CAR-T Label Update

on

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

on

FDA Grants Regeneron Two Eylea HD Approvals in One Day

on

Closed Loop Medicine Secures Additional Key GLP-1 Patent for Its AI-Based Dosing Platform: Powering Personalized, Direct-to-Patient Therapies

on

Pfizer Acquires Metsera to Compete with Zepbound in Obesity Market

on

Eisai Secures FDA Approval for Leqembi Autoinjector for Maintenance Dosing in Alzheimer’s Patients

on

Regeneron Faces Another FDA CRL for Eylea HD, Predicts August PDUFA Delay

on

FDA Approves Updated Dosing for Lilly's Kisunla to Lower Brain Swelling Risk

on

FDA Approves CSL's Andembry, Directly Competing With Takeda's Takhzyro in HAE

on

Leqembi's Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost

on

FDA rejection of extended dosing interval is another piece of bad news for Regenerons Eylea HD

on

LB-102: Promising Phase 2 Results Revive Benzamide Antipsychotics for Schizophrenia Treatment in the US

on

Eisai Anticipates Growth Acceleration for Alzheimer's Drug Leqembi Despite Slow Initial Uptake

on

FDA Approves Extended Dosing for Astellas' Izervay, Intensifying Competition in Geographic Atrophy Treatment

on

FDA Approves Extended Dosing for Astellas' Izervay in Geographic Atrophy Treatment

on